HHS Issues Compounding Peptides Restrictions as DOL Mandates PBM Rebate Disclosures

The HHS rule ends broad compounding exemptions once FDA declared shortages resolved for GLP-1 agonists, shifting patients toward branded products at list prices exceeding $1,000 monthly. This follows FDA guidance updates in 2024-2025 that already narrowed 503A/503B pathways. Compounding pharmacies had supplied up to 40 percent of semaglutide demand during peak shortages per industry estimates, creating abrupt access gaps for cash-pay and uninsured users.

PBM disclosure requirements target spread pricing and manufacturer fees that steer formularies, building on prior CMS and state efforts. Self-insured employers, covering roughly 60 percent of insured workers, gain granular data on net costs and steering incentives previously hidden in aggregate reports. Early modeling from health economists projects potential 8-12 percent rebate pass-through to plan sponsors if enforcement holds, though litigation risk remains high.

The dual actions link drug pricing transparency to manufacturing controls, amplifying effects on affordability. Observational data from 2023-2025 show compounded GLP-1 versions reduced out-of-pocket costs by 50-70 percent for some users before restrictions. Next steps include FDA enforcement actions and potential congressional hearings on whether policy favors manufacturers over patient access.